Candida & Candidiasis

Candida infections are the most important cause of fungal morbidity and mortality, yearly accounting for 140 million mucosal infections and 750,000 life-threatening bloodstream infections. Fighting the deadly candidiasis with the few available antifungal agents remains challenging. Notably, novel multi-drug resistant Candida species continue to emerge globally in hospital environments, including Candida auris. Much is known about the ‘big four’ of candidiasis causing species: Candida albicans, Candida glabrata, Candida tropicalis, and Candida parapsilosis, but the less common but emerging Candida species are not well-covered. We welcome all submissions for this special collection of Mycopathologia. We encourage a focus on epidemiology, nomenclatural and taxonomical issues, improved Candida diagnostics, antifungal susceptibility and resistance mechanisms, and novel therapy.


  • Ferry Hagen

    Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands; E-mail: Medical mycology, Molecular diagnostics, Taxonomy, Cryptococcus, Candida, Molecular typing, Epidemiology

  • Nancy Wengenack

    Mayo Clinic, Rochester, MN, USA

  • Patrick Woo


  • Jesús Guinea

    Hospital General Universitario Gregorio Marañón, Madrid, Spain

  • Samantha Jacobs

    Associate Professor of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai

  • Vishnu Chaturvedi

    Westchester Medical Center, Valhalla, NY, USA


Articles will be displayed here once they are published.